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Abstract Multidrug resistance (MDR) phenotypes have been
associated with the overexpression of various members of the
superfamily of ATP binding cassette (ABC) transporters. Here
we demonstrate that a member of the ABC-transporter family,
the heterodimer ‘transporter associated with antigen processing’
(TAP), physiologically involved in major histocompatibility
complex class I-restricted antigen presentation, is significantly
overexpressed in the human gastric carcinoma cell line EPG85-
257RNOV exhibiting a mitoxantrone-resistant phenotype. This
tumor cell line shows an atypical MDR phenotype in the absence
of ‘P-glycoprotein’ or ‘MDR-associated protein’ overexpression
but with an enforced ‘breast cancer resistance protein’ expression
level. Transfection of both TAP subunits encoding cDNA
molecules, TAP1 and TAP2, into the drug-sensitive parental
gastric carcinoma cell line EPG85-257P conferred a 3.3-fold
resistance to mitoxantrone but not to alternative anti-neoplastic
agents. Furthermore, cell clones transfected with both, but not
singularly expressed TAP1 or TAP2, reduced cellular mitoxan-
trone accumulation. Taken together, the data suggest that the
heterodimeric TAP complex possesses characteristics of a
xenobiotic transporter and that the TAP dimer contributes to
the atypical MDR phenotype of human cancer cells. ß 2001
Published by Elsevier Science B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
The multidrug resistance (MDR) phenotype typically oc-
curs after exposure to chemotherapeutic agents. The MDR
phenomenon can result from the overexpression of members
of the ATP binding cassette (ABC) superfamily of transmem-
brane transporters that mediate the ATP-driven unidirectional
transport of a broad range of compounds across biological
membranes. Evidence is emerging that the molecular basis of
acquired MDR is multifactorial. Historically, a MDR pheno-
type that is accompanied by enhanced activity of the ABC-
transporter ‘P-glycoprotein’ (P-gp) [1] is designated as classi-
cal MDR, while MDR phenotypes in the absence of P-gp are
named atypical MDR or non-P-gp-mediated MDR. Various
mechanisms conferring atypical MDR have been described,
including overexpression of alternative ABC-transporters,
e.g. members of the MDR protein’ (MRP) family (overview
in [2]) or breast cancer resistance protein (BCRP) (overview in
[3]).
To address the problem of atypical MDR, we previously
established a cell culture model in vitro. The human gastric
carcinoma cell line EPG85-257P exhibiting a high sensitivity
against various antitumor drugs was chosen to select the atyp-
ical MDR variant EPG85-257RNOV [4] and the classical
MDR variant EPG85-257RDB [5] by treatment with stepwise
increasing concentrations of mitoxantrone or daunorubicin.
Characterization of the atypical MDR phenotype in the gas-
tric carcinoma cells revealed a vesicular compartmentalization
of mitoxantrone in the absence of P-gp production [3,4] or
distinct MRP1 overexpression [6]. Furthermore, it could be
demonstrated that the BCRP encoding mRNA is much
more pronounced in the atypical MDR cell line EPG85-
257RNOV when compared to the parental, non-resistant cells
or the classical MDR derivative [3,7]. However, the current
hypothesis of acquired atypical MDR is based on the concept
that this phenotype consists of various molecular mechanisms
that are simultaneously active. Hence, mechanisms, as yet
unknown, may contribute to the atypical MDR phenotype
exhibited by the gastric carcinoma cell line EPG85-257RNOV.
The ‘transporter associated with antigen processing’ (TAP)
represents an additional member of the ABC-transporter
superfamily (overview in [8]). TAP, a heterodimer formed by
TAP1 and TAP2 subunits, physiologically plays a major role
in major histocompatibility complex (MHC) class I-restricted
antigen presentation by mediating peptide translocation over
the endoplasmic reticulum (ER) membrane [9]. TAP1 and
TAP2 are homologous polypeptides each possessing a hydro-
phobic N-terminal domain and a C-terminal ABC domain.
Both monomers are required for peptide binding and trans-
location, preferentially peptides of 8^15 amino acid residues.
It has been reported that overexpression of TAP could be
detected in MDR cell lines by using a TAP1-speci¢c antise-
rum [10]. Moreover, the study demonstrated that expression
of rat cDNAs encoding TAP1 and TAP2 subunits in the
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TAP-de¢cient lymphoblastoid cell line T2 could lead to a
slightly elevated tolerance to etoposide. In this study, we in-
vestigated the role of the human TAP in an acquired atypical
MDR phenotype that was induced by mitoxantrone exposure
of human gastric carcinoma cells in vitro and postulate that
the TAP heterodimer exhibits characteristics of a xenobiotic
transporter and contributes to the development of an atypical
MDR phenotype in human cancer cells.
2. Materials and methods
2.1. Cell culture
The establishment and characterization of the human gastric carci-
noma cell line EPG85-257P and their corresponding atypical MDR
subline EPG85-257RNOV and their classical MDR variant EPG85-
257RDB have been described previously [4,5]. These tumor cells were
grown in Leibovitz L 15 medium (Bio Whittaker, Walkersville, MD,
USA) supplemented by 10% fetal calf serum (Gibco BRL, Grand
Island, NY, USA), 1 mM L-glutamine, 6.25 mg/l fetuin, 80 IE/l in-
sulin, 2.5 mg/l transferrin, 1 g/l glucose, 1.1 g/l NaHCO3, 1% minimal
essential vitamins, and 20 000 kIE/l trasylol in a humidi¢ed atmos-
phere of 5% CO2 at 37‡C. Additionally, the classical MDR line
EPG85-257RDB was grown by adding 2.5 Wg/ml daunorubicin and
the atypical MDR variant EPG85-257RNOV was grown at mitoxan-
trone concentrations of 0.2 Wg/ml. Transfected TAP1 cDNA expres-
sion vector containing cell clones were cultivated by adding 400 Wg/ml
G418 (Invitrogen, San Diego, CA, USA), transfected TAP2 cDNA
expressing clones were cultivated in the presence of 400 Wg/ml zeocin
(Invitrogen), and TAP1 and TAP2 cotransfected clones were grown in
the presence of both antibiotics.
2.2. Drugs
The following cytotoxic and antibiotic agents were used: mitoxan-
trone (Lederle, Wolfratshausen, Germany); daunorubicin and doxo-
rubicin (Farmitalia Carlo Erba, Freiburg, Germany); cisplatin, etopo-
side and paclitaxel (Bristol-Myers, Munich, Germany); vincristine
(Lilly, Giessen, Germany); G418 and zeocin (Invitrogen, San Diego,
CA, USA).
2.3. Northern blot analysis
Northern blot analyses were performed as described previously [11].
Brie£y, total RNA was prepared using RNAzol reagent (Gibco BRL,
Grand Island, NY, USA) according to the manufacturer’s instruc-
tions. 20 Wg of total cellular RNA were fractionated on 1% aga-
rose^formaldehyde gels and transferred onto a Hybond-N membrane
(Amersham, Aylesbury, UK). Blots were hybridized with a 2.8 kb
TAP1 or a 2.5 kb TAP2 encoding cDNA probe labeled with
[32P]dCTP by random primed labeling (Amersham). Blots were incu-
bated with 25 ng labeled cDNA probe in 6USSPE, 10% dextran sul-
fate, 7% SDS and 0.5% Blotto at 65‡C, for 16 h. Finally, the mem-
brane was washed under high stringency conditions (0.1USSC, 1%
SDS at 60‡C). As control for the fact that equivalent amounts of
RNA were analyzed, the membranes were rehybridized with a 1.2 kb
‘phosphoglycerate kinase’ (PGK) cDNA probe.
2.4. Western blot analyses
For detection of TAP1 and TAP2, proteins were isolated as de-
scribed previously [11]. In brief, cellular extracts were prepared by
lysing 108 exponentially growing PBS-washed cells in Ripa lysis bu¡er
(50 mM Tris^HCl (pH 7.4), 5 mM EGTA, 150 mM NaCl, 1% (v/v)
Triton X-100, 0.1% (w/v) SDS) supplemented with 1% (w/v) trasylol
and Complete1 protease inhibitor cocktail (Roche Diagnostics,
Mannheim, Germany) for 30 min at 4‡C. The cell lysate was centri-
fuged at 20 000Ug for 10 min at 4‡C. Supernatant was merged 1:4
with sample bu¡er (120 mM Tris^HCl (pH 6.8), 300 mM DTT, 4%
SDS, 20% glycerol, 0.3% bromophenol blue), heated for 10 min at
98‡C, centrifuged at 20 000Ug for 5 min at 4‡C and stored at 380‡C.
Before SDS^PAGE protein extracts were quantitated using amido
black staining [12]. Samples of 20 Wg of proteins each were loaded
onto a 10% SDS^PA gel. Separated proteins were transferred to a
0.2 Wm cellulose nitrate membrane (Schleicher and Schuell, Dassel,
Germany). To avoid unspeci¢c binding, the ¢lters were incubated in
5% non-fat dry milk, 0.1% Tween 20 in TBS overnight. Subsequently,
¢lters were incubated with mouse monoclonal antibody 148.3 directed
against TAP1 [13], or mouse monoclonal antibody 429.3 directed
against TAP2 [14] 1:20 diluted in the same solution for 2 h and,
afterwards, with peroxidase-conjugated rabbit anti-mouse IgG
(1:5000) (Jackson Immunoresearch Laboratories, West Grove, PA,
USA). The protein^antibody complexes were visualized by chemolu-
minescence (ECL system, Amersham) according to the manufacturer’s
protocol. Immunoblot reactions were carried out using at least three
independent protein extracts.
2.5. Preparation of TAP containing crude membranes and
peptide binding assay
Cells were thawn on ice in 10 mM Tris pH 8.0 supplemented with
protease inhibitors (50 Wg/ml AEBSF, 1 Wg/ml aprotinin, 150 Wg/ml
benzamidine, 10 Wg/ml leupeptin, 5 Wg/ml pepstatin) and 1 mM DTT
and homogenized with a glass homogenizer. Lysed cells were centri-
fuged at 1000Ug for 10 min. For collection of crude membranes
supernatant was centrifuged at 200 000Ug for 30 min and pellets
were resuspended in PBS. Protein concentrations of the crude mem-
branes were determined by micro bicinchoninic acid protein assay
(Pierce). Aliquots were frozen in liquid nitrogen and stored at
380‡C. Peptide binding to the heteromeric TAP molecule was assayed
as reported previously [15] with the di¡erence that the peptide was
labeled with 125I instead of £uorescein.
2.6. Transfection and enforced expression of TAP1 and TAP2 in
EPG85-257P cells
For construction of TAP1 and TAP2 eukaryotic expression vectors
the 2.8 kb TAP1 encoding cDNA (both TAP monomer encoding
cDNA clones were kindly provided by J. Trowsdale, Immunology
Division, Department of Pathology, Cambridge, UK) was cloned
into the XhoI site of the mammalian expression vector pcDNA3 (In-
vitrogen). The TAP1 cDNA does not contain the frameshift of the
originally published clone [16]. For the expression of TAP2, a 2.5 kb
cDNA XhoI fragment which represents a RING11A allele [17] was
cloned into the pcDNA3.1Zeo(+) (Invitrogen) expression vector. Fol-
lowing subcloning of the constructs, a DNA sequence analysis was
performed to con¢rm that the inserts of the selected clones were in a
sense orientation to the cytomegalovirus (CMV) promoters of the
vectors. Both TAP subunit encoding expression constructs were simul-
taneously transfected into the parental, drug-sensitive human gastric
carcinoma cell line EPG85-257P using liposome transfer (DMRIE,
Qiagen, Hilden, Germany). Stably transfected cell clones were ob-
tained by using G418 and zeocin as selecting agents. As controls,
EPG85-257P cells were also transfected with unique TAP1 or TAP2
constructs and empty expressing vectors. Subclones were tested for
expression of TAP1 and TAP2 encoding mRNAs by RT-PCR and
Northern blot analysis.
2.7. Cytotoxicity assay for cell survival
Chemoresistance was tested using a proliferation assay basing on
sulforhodamine B (SRB), a protein binding reagent [18]. Cells were
distributed into 96 well plates at a concentration of 200 cells/well. For
adhesion and resumption the cells in the logarithmic growth phase
were incubated for 48 h prior to drug application. After 5 days of
drug treatment, the assay was terminated by removal of the media
and the addition of chilled 10% trichloroacetic acid. After a 1 h in-
cubation at 4‡C wells were washed ¢ve times with tap water and cell-
associated protein was stained by adding 0.4% SRB in 1% acetic acid
for 10 min at room temperature. Absorbance was measured at 540 nm
after drying and re-solubilization in 20 mM Tris^HCl (pH 10). For
determination of IC50-values of antitumor agents, cells were incubated
with increasing concentrations of drugs, whereby the absorbance dif-
ference of control cells without drug was set to be 100%. Graphs of
cell survival against dose of anti-neoplastic agent were plotted, and
IC50-values were calculated from multiple, at least three independent
experiments for each cell clone.
2.8. Mitoxantrone accumulation assay
Cellular mitoxantrone accumulation was determined according to a
procedure described by others [19]. Brie£y, 4U105 cells were seeded
out in 6 well plates 24 h prior to the experiment. Incubation with
mitoxantrone (0, 1, 5 and 10 Wg/ml) was performed for 60 min at
37‡C and 70^80% cellular con£uence. Cells were washed with ice-
cold PBS, trypsinized and resuspended in 4‡C medium at a concen-
tration of 4U105 cells/ml. Intracellular £uorescence of mitoxantrone
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was determined by £ow cytometry (Becton-Dickinson, San Jose, CA,
USA). The cells were excited at 480 nm and emission was measured at
630 nm. A minimum of 104 cells was analyzed for each sample. All
assays were performed at least in three independent experiments, each
time with triplicate wells.
3. Results
3.1. Expression of TAP1 and TAP2 encoding mRNAs in
MDR gastric carcinoma cell lines
In order to verify the hypothesis that the heterodimeric
ABC-transporter TAP contributes to the MDR phenotypes
exhibited by di¡erent MDR human gastric carcinoma cell
lines, mRNA expression analyses were performed. As shown
in Fig. 1, Northern blot analysis revealed that the expression
levels of both TAP monomer encoding mRNAs, TAP1 and
TAP2, are much more pronounced in the atypical MDR gas-
tric carcinoma cell line EPG85-257RNOV when compared to
the drug-sensitive, parental EPG85-257P cells or the classical
MDR subline EPG85-257RDB. Only traces of TAP1 and
TAP2 encoding mRNAs could be detected in the tumor cell
lines EPG85-257P and EPG85-257RDB. This analysis sup-
ported the idea that TAP may be involved in the atypical
MDR phenotype, but not in the classical MDR phenomenon.
3.2. Overexpression of TAP1 and TAP2 in transfected gastric
carcinoma cells
Transfection experiments using TAP1 and TAP2 cDNA
containing expression vector constructs were performed to
demonstrate that a drug-resistant phenotype could be trans-
ferred to former drug-sensitive cells by the transmembrane
transporter TAP. After selection with antibiotics, several sta-
ble TAP1 and TAP2 transfectant clones and TAP1/TAP2 co-
transfectant clones were obtained. These transfectants demon-
strated no gross morphological changes in comparison to the
original cell line EPG85-257P (data not shown). Starting from
these clones, in each case 10 antibiotics-resistant TAP1/TAP2
cotransfected and simply TAP1 or TAP2 subunit cDNA-
transfected clones and control clones containing an empty
expression vector were analyzed for mitoxantrone resistance
using a cell proliferation assay. Two of 10 TAP1/TAP2 co-
transfected clones showed an increased tolerance to mitoxan-
trone exposure when compared to the non-resistant cell line
EPG85-257P. None of the control clones, transfected with
TAP1 cDNA, or TAP2 cDNA alone, or an empty expression
vector showed any modulation in mitoxantrone resistance. In
each case one clone was chosen to examine TAP expression in
detail. The CMV promoter-driven overexpression of TAP1
and TAP2 encoding mRNAs in the transfected cell clones
derived from the human gastric carcinoma cell line EPG85-
257P and controls was con¢rmed by Northern blot analysis
on the mRNA level (Fig. 2A) and Western blot analysis on
the protein level (Fig. 2B). These analyses demonstrated that
an elevated expression level of the TAP1 encoding mRNA
could be observed in the TAP1 cDNA transfected cell line
EPG85-257P/TAP1 and in the double-transfected clone
EPG85-257P/TAP1/2. As expected, an enforced mRNA ex-
pression level of TAP2 was detected in the TAP2 cDNA
transfected line EPG85-257P/TAP2 and the double-trans-
fected cell line EPG85-257P/TAP1/2. The Western blot anal-
ysis could demonstrate that the double-transfected cell line
EPG85-257P/TAP1/2 showed an enhanced cellular protein
content of both TAP subunits, respectively. Furthermore, in
the TAP2-transfected clone EPG85-257P/TAP2 and the atyp-
Fig. 1. Northern blot analysis of TAP1 and TAP2 mRNA expres-
sion in human gastric carcinoma cells using a 2.8 kb TAP1-speci¢c
cDNA probe and a 2.5 kb TAP2-speci¢c cDNA probe. As control,
the blots were probed with a 1.8 kb cDNA probe of PGK. The
atypical MDR gastric carcinoma cells line EPG85-257RNOV exhib-
its a distinct overexpression of both TAP subunit encoding mRNAs
when compared to the drug-sensitive cell line EPG85-257P and the
classical MDR variant EPG85-257RDB.
Table 1
Cross-resistance of TAP expressing cells against various anti-neoplastic drugs
Drug Cell type
EP85-257P
IC50 (RF)
EPG85-257P/
pcDNA3 IC50 (RF)
EP85-257P
257P/TAP1 IC50 (RF)
EP85-257P
257P/TAP2 IC50 (RF)
EP85-257P
257P/TAP1/2 IC50 (RF)
Mitoxantrone (ng/ml) 2.81 (1.0) 2.74 (1.0) 3.66 (1.3) 3.11 (1.1) 9.13 (3.3)
Etoposide (ng/ml) 92.75 (1.0) 55.87 (0.6) 70.50 (0.8) 78.60 (0.9) 102.00 (1.1)
Cisplatin (Wg/ml) 2.25 (1.0) 2.00 (0.9) 1.85 (0.8) 1.60 (0.7) 1.98 (0.9)
Paclitaxel (ng/ml) 2.45 (1.0) 1.85 (0.8) 1.88 (0.8) 2.14 (0.9) 2.75 (1.1)
Daunorubicin (ng/ml) 4.35 (1.0) 4.05 (0.9) 4.65 (1.1) 4.50 (1.0) 4.50 (1.0)
Vindesine (ng/ml) 0.358 (1.0) 0.370 (1.0) 0.369 (1.0) 0.197 (0.6) 0.430 (1.2)
RF, resistance factor (x-fold). RF was calculated by dividing the IC50 value of a given drug of a transfected cell line against the IC50 value of
the non-transfected, parental cell line EPG85-257P.
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ical MDR carcinoma line EPG85-257RNOV, an elevated cel-
lular protein content of the TAP2 polypeptide could be de-
tected while in the remaining cells including TAP1 transfec-
tants and empty vector control transfectants only a
constitutive TAP2 content could be observed. Likewise, in
the TAP1-transfected clone EPG85-257P/TAP1 and in the
atypical MDR cell line EPG85-257RNOV, an increased cel-
lular concentration of the TAP1 subunit could be detected as
well as in the non-resistant, parental cell line EPG85-257P and
the classical MDR variant EPG85-257RDB a constitutive
TAP1 content could be observed. However, in the controls
EPG85-257P/TAP2 and EPG85-257P/pcDNA3 an increased
cellular TAP1 polypeptide content could be observed even
though those clones were not transfected with the TAP1 en-
coding expression vector construct, indicating that the ele-
vated cellular TAP1 content might be caused by a decreased
cellular TAP1 turnover rate, e.g. mediated by stabilization of
TAP1 by enhanced complex formation with TAP2.
3.3. Determination of cellular heteromeric TAP
A peptide binding assay was performed to evaluate if the
clones overexpressing TAP1 and TAP2 showed an increased
cellular content of heteromeric TAP. Fig. 3 demonstrates that
a 4.6-fold increased heteromeric TAP content could be de-
tected in the atypical MDR cell line EPG85-257RNOV
when compared to the non-resistant, parental cell line
EPG85-257P. The classical MDR line EPG85-257RDB
showed a slightly 1.9-fold increased heteromeric TAP amount.
The TAP1 and TAP2 cotransfected cell line EPG85-257P/
TAP1/2 showed a 3.9-fold enhanced heteromeric TAP content
while the control clone EPG85-257P/pcDNA3, transfected
with an empty expression vector showed no enhanced hetero-
meric TAP concentration. Likewise, a slightly enhanced het-
eromeric TAP content could be observed in the simply trans-
fected cell lines EPG85-257P/TAP1 (1.7-fold) and EPG85-
257P/TAP2 (1.9-fold).
Fig. 3. Relative cellular content of heteromeric ABC-transporter
TAP as determined by a peptide binding assay. in the non-resistant,
parental cell line EPG85-257P and its atypical MDR derivative
EPG85-257RNOV as well as TAP1/TAP2 cotransfected cells and
TAP1, TAP2, and empty expression vector transfectants.
Fig. 2. A: Northern blot analysis of TAP1 and TAP2 mRNA ex-
pression in TAP1 and TAP2 cDNA-transfected cell clones derived
from the non-resistant, parental gastric carcinoma cell line EPG85-
257P. The double-transfected cell line EPG85-257P/TAP1/2 shows
expression of both TAP subunit encoding mRNAs while the simply
TAP1 or TAP2 transfected clones, EPG85-257P/TAP1 and EPG85-
257P/TAP2, only overexpress the corresponding mRNA molecule.
Control transfectants, EPG85-257P/pcDNA3, transfected with an
empty expression vector, the non-resistant cell line EPG85-257P and
the classical MDR cell line EPG85-257RDB show only weak expres-
sion of TAP encoding mRNAs. As expected, the atypical MDR line
EPG85-257RNOV shows expression of both TAP encoding
mRNAs, respectively. In the case of the TAP2 encoding mRNA,
the band is not visible due to the short exposure time. Longer expo-
sure time con¢rmed TAP2 mRNA expression as demonstrated in
Fig. 1. As a control, the blots were probed with a PGK cDNA. B:
Western blot analysis of TAP1 and TAP2 subunit synthesis in
TAP1 and TAP2 cDNA-transfected cell clones derived from the
non-resistant, parental gastric carcinoma cell line EPG85-257P. The
double-transfected cell line EPG85-257P/TAP1/2 shows a speci¢c
protein band of both TAP subunits, respectively. In the TAP2-trans-
fected cell line EPG85-257P/TAP2 and the atypical MDR cell line
EPG85-257RNOV, an enforced synthesis of the TAP2 subunit could
be detected while the remaining cell lines showed only a constitutive
TAP2 polypeptide content. In the TAP1-transfected clone EPG85-
257P/TAP1 and in the atypical MDR cell line EPG85-257RNOV,
an enhanced cellular content of the TAP1 polypeptide could be de-
tected. As expected the non-resistant, parental cell line EPG85-257P
and the classical MDR variant EPG85-257RDB showed only a con-
stitutive cellular TAP1 content while the non-TAP1-transfected con-
trols EPG85-257P/TAP2 and EPG85-257P/pcDNA3 exhibited an in-
crease in cellular TAP1 polypeptide.
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3.4. Drug resistance of TAP1 and TAP2 cotransfected cells
The sensitivities of the various transfected sublines to che-
motherapeutic agents were tested by a modi¢ed SRB-based
proliferation assay [18]. As shown in Table 1, it could be
demonstrated that the TAP1 and TAP2 cotransfected clone
EPG85-257P/TAP1/2 displayed a 3.3-fold resistance to mitox-
antrone when compared with the parental, non-resistant gas-
tric carcinoma cell line EPG85-257P. None of the control
transfectants, unique TAP1-transfected gastric carcinoma cells
EPG85-257P/TAP1, or simply TAP-2 transfected EPG85-
257P/TAP2 cells, or clones obtained by transfection with the
empty expression vector EPG85-257P/pcDNA3 showed any
signi¢cant elevated resistance level against mitoxantrone.
Likewise, Table 1 demonstrates that no noteworthy cross-re-
sistance against various commonly used anti-neoplastic drugs
including etoposide, cisplatin, paclitaxel, daunorubicin or vin-
desine could be induced in this cell culture model by cotrans-
fection with human TAP1 and TAP2 encoding cDNAs.
3.5. Mitoxantrone accumulation in TAP1 and TAP2
expressing gastric carcinoma cells
As shown in Fig. 4, it could be demonstrated that mitox-
antrone-resistant atypical MDR gastric carcinoma cells
EPG85-257RNOV exhibited no signi¢cant accumulation of
mitoxantrone whereas in the drug-sensitive parental cell line
EPG85-257P a considerable mitoxantrone-speci¢c £uores-
cence could be observed. However, the TAP1 and TAP2
cDNA cotransfected gastric carcinoma clone EPG85-257P/
TAP1/2 slightly decreased the mitoxantrone-speci¢c £uores-
cence signal. The unique TAP monomer, TAP1 or TAP2,
cDNA transfected cells or the empty expression vector trans-
fected controls showed a mitoxantrone accumulation that was
comparable with mitoxantrone accumulation observed in the
non-transfected, non-resistant, parental cell line EPG85-257P.
4. Discussion
In this study, we investigated the hypothesis that an in-
creased expression of the ABC-transporter TAP might be in-
volved in the acquired drug resistance phenotype exhibited by
the atypical MDR human gastric carcinoma cell line EPG85-
257RNOV. Primarily, we could demonstrate that the expres-
sion of both TAP subunit encoding mRNAs, TAP1 and
TAP2, is much more pronounced in these atypical MDR cells,
indicating that the TAP complex indeed contributes to the
acquired drug-resistant phenotype exhibited by this gastric
carcinoma cell line. In order to demonstrate that TAP could
mediate drug resistance to formerly drug-sensitive cancer cells,
we cotransfected the parental human gastric carcinoma cell
line EPG85-257P with CMV promoter-driven human TAP1-
and TAP2-encoding cDNA expression vector constructs. By
this approach the TAP1 and TAP2 mRNA and protein ex-
pression levels were considerably enhanced in the transfected
clones when compared to the non-transfected cells. Applying
this experimental strategy it was possible to achieve a cellular
heteromeric TAP polypeptide content in the transfected clones
that was similar to that TAP level observed in the drug-resis-
tant cell line with acquired atypical MDR. TAP1 and TAP2
overexpressing cells derived from the cell line EPG85-257P
showed a 3.3-fold increase in mitoxantrone resistance at the
IC50 level compared to non-transfected EPG85-257P cells and
controls accessed by cell proliferation assays. The fact that
several TAP1 and TAP2 cotransfected clones and none of
the controls increased their tolerance to mitoxantrone expo-
sure supports the idea that the new phenotype exhibited by
the cotransfected clones is indeed caused by TAP overexpres-
sion and not by unspeci¢c clonal e¡ects. The data presented
here strongly support the conclusion that the ABC-transport-
er protein family member TAP possesses characteristics of an
ATP-dependent xenobiotic transporter that plays a role in the
atypical MDR phenotype of human gastric carcinoma cells.
The overexpression of both TAP monomers in the atypical
MDR cell line EPG85-257RNOV suggests a role for TAP in
resistance to anti-neoplastic agents in human cancer cells.
TAP overexpression is, in general, paralleled by an en-
hanced expression of MHC I molecules. Since no increase in
MHC I expression could be observed in the atypical MDR
cell line EPG85-257RNOV or in any of the TAP1 or TAP2
transfected or cotransfected clones (data not shown), it seems
obvious that the TAP-mediated alteration in mitoxantrone
tolerance in these cells is an MHC I independent phenome-
non.
The exact molecular events by that the TAP-mediated alter-
ations in mitoxantrone susceptibility are e¡ected are not
understood in detail. However, it could be demonstrated
that the enhanced mitoxantrone resistance of TAP1 and
TAP2 cDNA cotransfected clones is accompanied by a de-
creased cellular mitoxantone-speci¢c £uorescence indicating
that the drug was exported from the cells. Physiologically,
the heterodimeric TAP complex is located on intracellular
membranes of the ER. TAP translocates short peptides which
were prior generated mostly by proteasome-mediated antigen-
ic protein degradation in the cytosol, into the lumen of the
Fig. 4. Accumulation of mitoxantrone as measured by £ow cytomet-
ry in the non-resistant, parental cell line EPG85-257P and its atypi-
cal MDR derivative EPG85-257RNOV as well as TAP1/TAP2 co-
transfected cells and TAP1, TAP2, and empty expression vector
transfectants. Drug accumulation is shown as a function of increas-
ing concentrations of mitoxantrone after 60 min drug incubation.
Displayed values represent the mean, the vertical error bars S.D. of
at least three replicate experiments.
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ER. In the ER lumen, the TAP-complexed peptides interact
with assembled MHC class I heavy chain-L2-microglobulin
heterodimers, leading to the transfer of the peptides, subse-
quent TAP dissociation from the complex and export of pep-
tides bound to MHC class I molecules to the Golgi apparatus
and ultimately to the cell surface. The human TAP complex
shows a preference for peptides with hydrophobic or basic
amino acids at the C-terminus. Hence, it is tempting to spec-
ulate that the heterodimeric TAP complex may mediate the
translocation of hydrophobic antitumor agents, such as
mitoxantrone, into the ER lumen. Since cellular vesicles, in
general, are derived from the ER, the TAP-mediated drug
translocation may be one step in the vesicular compartmen-
talization of mitoxantrone which was observed in the atypical
MDR gastric carcinoma cell line previously [3,4].
In contrast to the observations by Izquierdo et al. [10], who
transfected rat TAP complex encoding cDNAs into lympho-
blastoid T2 cells and conferred mild resistance to etoposide,
vincristine and doxorubicin (2^2.5-fold), our study could not
demonstrate that the human TAP dimer mediates resistance
to those anticancer agents in gastric carcinoma cells. Since
Izquierdo et al. [10] did not analyze the drug sensitivity of
their transfected clones against mitoxantrone, it is not clear
whether these discrepancies are due to di¡erences in the sub-
strate speci¢city of human and rat TAP complexes, utilization
of cellular models of di¡erent entities, or whether the used
cDNA expression vector constructs were not adapted for
achievement of su⁄cient cellular amounts of biological active
TAP complexes.
The value of a 3.3-fold increase in mitoxantrone resistance
in this cellular in vitro model is not dramatic. However, a
huge alteration in the drug-resistant phenotype may not to
be expected since it was demonstrated that alternative mech-
anisms such as vesicular compartmentalization [3,4] altera-
tions in DNA topoisomerase IIK expression [6] and enhanced
expression of BCRP [3,7] can be associated with the acquired
mitoxantrone-resistant phenotype exhibited by EPG85-
257RNOV cells. Furthermore, additional candidate factors
were identi¢ed [20,21] that might play a potential role in the
mitoxantrone resistance of these cells. On the other hand, it is
important to note that the e¡ect of change in drug tolerance
associated with alterations in TAP1 and TAP2 mRNA expres-
sion levels has implications and is of clinical signi¢cance. In
the clinical situation, a 2-fold increase in drug resistance is
su⁄cient to circumvent a successful chemotherapeutic treat-
ment of malignant cells. Thus, for the oncologist it is critical
to take into consideration that changes in TAP expression
level may be involved in a multimodal mechanism leading
to therapy resistance of human cancers.
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